ERBB2 and breast cancer: Among the 75 patients with HER2-positive breast cancer, 47 patients received targeted therapy and seven of these patients showed recurrence and metastasis; 28 patients did not receive targeted therapy and 13 of these patients showed recurrence or metastasis.